Your session is about to expire
← Back to Search
Immunomodulator
Single Arm for Cutaneous T-Cell Lymphoma
Phase < 1
Waitlist Available
Led By Ali Dana, MD
Research Sponsored by James J. Peters Veterans Affairs Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
This trial is studying how well using a combination of antibiotics and imiquimod works in treating patients with cutaneous T-cell lymphoma.
Eligible Conditions
- Cutaneous T-Cell Lymphoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pilot assessment of response.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment2 Interventions
Doxycycline 100 mg PO BID x 14 days, then Imiquimod up to 2 packs 3/ week x 28 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Imiquimod
FDA approved
Doxycycline
FDA approved
Find a Location
Who is running the clinical trial?
James J. Peters Veterans Affairs Medical CenterLead Sponsor
57 Previous Clinical Trials
2,892 Total Patients Enrolled
Ali Dana, MDPrincipal InvestigatorJames J. Peters VAMC
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger